The most common haematological adverse events of grade 3 or higher were leucopenia ( 21 [ 8 % ] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [ 2 % ] of 250 given SOX plus bevacizumab ; p = 00029 ) and neutropenia ( 84 [ 34 % ] vs 22 [ 9 % ] ; p < 00001 ) .